Duopharma Biotech Berhad saw strong growth in the third quarter ended 30 September 2024, with a revenue of RM208.73 million in the quarter, taking the cumulative revenue for FY2024 to date to RM620.02 million. The year-to-date revenue for FY2024 maintained a growth trajectory, up 15.4% from the RM537.23 million recorded in the same period last year it said.
For the current quarter, PAT increased 60% to RM15.5 million compared to RM8.9 million recorded in the previous quarter.
Meanwhile, the cumulative profit before tax (PBT) and profit after tax (PAT) across the three quarters rose 11.3% and 7.7% respectively. The robust double-digit growth the group said was primarily driven by higher sales across key sectors,
particularly the public health segment. The sales performance also offset increased operational costs associated with the newly completed K3 facility and higher finance costs, thus generating growth in PBT and PAT in the period.
In Q3 FY2024, Duopharma Biotech paid an interim dividend of 1.0 sen per share (2023: first interim dividend of 0.5 sen per share) equivalent to RM9.62 million (2023:RM 4.81 million) in respect of financial year ending 31 December 2024. The Directors did not recommend an interim dividend for the current quarter ended 30 September 2024.
